FDA issues GRAS no objection letter for inulin from Jerusalem artichoke

The U.S. Food and Drug Administration (FDA) issued a GRAS (Generally Recognized As Safe) no objection letter for inulin derived from Jerusalem artichoke. Intrinsic Organics originally submitted the GRAS notice to the FDA on February 11, 2019, for use as a bulking agent in 43 food categories, including infant and toddler foods, ready-to-eat breakfast cereals, and other foods. According to Intrinsic Organics, the inulin is extracted from the tubers of Jerusalem artichoke (Helianthus tuberosus) and is available in either a brown syrup or a tan powder, each containing ≥80% carbohydrate on a dry basis, of which ≥65% is inulin.

Based on the scientific information that Intrinsic Organics provided, as well as other information available to the agency, the FDA determined that it had no questions at this time regarding Intrinsic Organics’ conclusion that inulin from Jerusalem artichoke is GRAS under its intended conditions of use.